Collaboration Advances EMA601 as Potential First-in-Class Stroke Therapy

Collaboration advances EMA601 as potential first-in-class stroke therapy

Boehringer Ingelheim and the Lower Franconian biotech company EMFRET Analytics have signed a cooperation and license agreement for the preclinical development program of the GPVI‑blocking antibody EMA601.

Promising GPVI Inhibitor Advances Toward Clinical Development for Stroke

In a landmark development in the field of stroke therapy and platelet biology, Boehringer Ingelheim, a global leader in pharmaceutical innovation, has entered into a strategic cooperation and license agreement with EMFRET Analytics GmbH & Co. KG, a cutting-edge biotech firm based in Lower Franconia, Germany. This partnership is centered around the preclinical advancement of EMA601, a pioneering GPVI-blocking antibody with the potential to revolu…

Stroke: Promising active substance is being further developed

30.03.2026 - Boehringer Ingelheim and the Lower Franconian company EMFRET Analytics want to advance an active substance for the treatment of strokes. Its roots lie in the Würzburg University Medicine.